Literature DB >> 10815920

Nuclear delivery of doxorubicin via folate-targeted liposomes with bypass of multidrug-resistance efflux pump.

D Goren1, A T Horowitz, D Tzemach, M Tarshish, S Zalipsky, A Gabizon.   

Abstract

Folic acid, attached to polyethyleneglycol-derivatized, distearoyl-phosphatidylethanolamine, was used to target in vitro liposomes to folate receptor (FR)-overexpressing tumor cells. Confocal fluorescence microscopic observations demonstrated binding and subsequent internalization of rhodamine-labeled liposomes by a high FR-expressing, murine lung carcinoma line (M109-HiFR cells), with inhibition by free folic acid. Additional experiments tracking doxorubicin (DOX) fluorescence with DOX-loaded, folate-targeted liposomes (FTLs) indicate that liposomal DOX is rapidly internalized, released in the cytoplasmic compartment, and, shortly thereafter, detected in the nucleus, the entire process lasting 1-2 h. FR-mediated cell uptake of targeted liposomal DOX into a multidrug-resistant subline of M109-HiFR cells (M109R-HiFR) was unaffected by P-glycoprotein-mediated drug efflux, in sharp contrast to uptake of free DOX, based on verapamil-blockade experiments with quantitation of cell-associated DOX and flow cytometry analysis. Delivery of DOX by FTLs to M109R-HiFR cells increased continuously with time of exposure, reaching higher drug concentrations in whole cells and nuclei compared with exposure to free DOX. The in vitro cytotoxic activity obtained with DOX-loaded FTLs was 10-fold greater than that of the nontargeted liposome formulation, but was not improved over that of free DOX despite the higher cellular drug levels obtained with the targeted liposomes in M109R-HiFR cells. However, if M109R-HiFR cells were exposed to drugs in vitro and tested in an in vivo adoptive assay for tumor growth in syngeneic mice along a 5-week time span, FTL DOX was significantly more tumor inhibitory than free DOX. It is suggested that the biological activity of liposomal DOX released inside the cellular compartment is reduced in vitro due to the aggregated state of DOX, resulting from the liposome drug-loading process, and requires a long period of time and/or an in vivo environment for full expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10815920

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  74 in total

1.  Development of multifunctional hyaluronan-coated nanoparticles for imaging and drug delivery to cancer cells.

Authors:  Mohammad H El-Dakdouki; David C Zhu; Kheireddine El-Boubbou; Medha Kamat; Jianjun Chen; Wei Li; Xuefei Huang
Journal:  Biomacromolecules       Date:  2012-03-13       Impact factor: 6.988

Review 2.  Drug transport to brain with targeted liposomes.

Authors:  Anita Schnyder; Jörg Huwyler
Journal:  NeuroRx       Date:  2005-01

Review 3.  Carrier-based strategies for targeting protein and peptide drugs to the lungs.

Authors:  Sally-Ann Cryan
Journal:  AAPS J       Date:  2005-03-24       Impact factor: 4.009

Review 4.  Nanosystems for simultaneous imaging and drug delivery to T cells.

Authors:  Tarek M Fahmy; Peter M Fong; Jason Park; Todd Constable; W Mark Saltzman
Journal:  AAPS J       Date:  2007-06-08       Impact factor: 4.009

5.  Antitumor effect of folate-targeted liposomal doxorubicin in KB tumor-bearing mice after intravenous administration.

Authors:  Kareen Riviere; Zhaohua Huang; Katherine Jerger; Nichole Macaraeg; Francis C Szoka
Journal:  J Drug Target       Date:  2010-03-30       Impact factor: 5.121

6.  Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery.

Authors:  Kathryn C Partlow; Gregory M Lanza; Samuel A Wickline
Journal:  Biomaterials       Date:  2008-05-16       Impact factor: 12.479

7.  Polyamidoamine dendrimers-based nanomedicine for combination therapy with siRNA and chemotherapeutics to overcome multidrug resistance.

Authors:  Jiayi Pan; Livia P Mendes; Momei Yao; Nina Filipczak; Sumanta Garai; Ganesh A Thakur; Can Sarisozen; Vladimir P Torchilin
Journal:  Eur J Pharm Biopharm       Date:  2019-01-08       Impact factor: 5.571

Review 8.  Nanovehicular intracellular delivery systems.

Authors:  Ales Prokop; Jeffrey M Davidson
Journal:  J Pharm Sci       Date:  2008-09       Impact factor: 3.534

9.  Co-delivery of doxorubicin and Bcl-2 siRNA by mesoporous silica nanoparticles enhances the efficacy of chemotherapy in multidrug-resistant cancer cells.

Authors:  Alex M Chen; Min Zhang; Dongguang Wei; Dirk Stueber; Oleh Taratula; Tamara Minko; Huixin He
Journal:  Small       Date:  2009-12       Impact factor: 13.281

10.  Peptide-mediated liposomal drug delivery system targeting tumor blood vessels in anticancer therapy.

Authors:  Han-Chung Wu; De-Kuan Chang
Journal:  J Oncol       Date:  2010-05-05       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.